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Human tissue kallikrein gene delivery attenuates hypertension, Tissue kallikrein is a serine proteinase present in many
renal injury, and cardiac remodeling in chronic renal failure. tissues, including those critical for blood pressure regula-
Background. Tissue kallikrein cleaves kininogen substrate tion and cardiovascular function, such as the kidney, vas-to produce the potent vasodilating peptide kinin, which plays
culature, lung, heart, and adrenals [1–3]. The best knownimportant roles in cardiovascular and renal function. To ex-
function of tissue kallikrein is the cleavage of low molec-plore cardiac and renal potential protective effects of kallikrein
gene delivery in chronic renal failure, we delivered adenovirus ular weight kininogen to release kinin, a peptide hormone
carrying the human tissue kallikrein cDNA (cHK) into rats that mediates a number of biological responses including
with 5/6 reduction of renal mass. increased local blood flow, smooth muscle relaxation orMethods. Expression of human tissue kallikrein in rats was
constriction, and increased vascular permeability [4]. Byassessed by enzyme-linked immunosorbent assay (ELISA) and
binding to endothelial bradykinin B2 receptors, kinin stim-reverse transcription-polymerase chain reaction (RT-PCR)/
Southern blotting. Physiological parameters monitored in rats ulates release of potent vasodilators, including prosta-
included systolic blood pressure, heart rate, and urinary excre- cyclin, nitric oxide, and endothelium-derived hyperpo-
tion of protein, albumin, kinin, cGMP, cAMP, and nitrate/
larizing factor [5]. Studies have shown that hypertensivenitrites. Systemic and regional hemodynamics were measured
patients, as well as genetically hypertensive rats, haveby fluorescent-labeled microspheres. Heart weight and myo-
cyte diameter were used to assess left ventricular hypertrophy. decreased urinary kallikrein levels [6–8]. A large family
Quantitative and qualitative morphological analyses were used pedigree study in Utah (USA) indicated that high uri-
to evaluate histologic changes in kidney and heart sections. nary kallikrein excretion, expressed as a dominant allele,
Results. Active tissue kallikrein reached a peak serum level
might have a protective effect against the developmentof 463 6 76 ng/mL following gene delivery and returned to
of hypertension [9]. We have created transgenic animalcontrol levels within 21 days. A maximal blood pressure reduc-
tion of 37 mm Hg was observed within one week in rats receiv- models with altered expression of kallikrein-kinin system
ing kallikrein gene delivery as compared with control rats re- components in order to provide direct evidence of their
ceiving adenovirus containing the luciferase gene (159 6 5 vs. role in blood pressure regulation [10–12]. Transgenic196 6 6 mm Hg, N 5 15, P , 0.001), and a significant blood
mice overexpressing human tissue kallikrein exhibited apressure difference continued for five weeks postgene delivery.
life-long reduction in blood pressure, and this effect wasKallikrein gene delivery significantly decreased total urinary
protein and albumin excretion and increased levels of urinary shown to be mediated by the bradykinin B2 receptor.
kinin, nitrite/nitrate, and cGMP levels. Cardiac output and Transgenics overexpressing human bradykinin B2 recep-regional blood flow were also increased, while peripheral vascu- tors are similarly hypotensive for life. The ability of kalli-lar resistance decreased. Kallikrein gene transfer reduced glo-
krein gene delivery to lower systemic blood pressure andmerular sclerotic lesions, tubular damage, lumenal protein cast
attenuate cardiovascular and renal injury in geneticallyaccumulation, and interstitial inflammation in the kidney. Myo-
cardial hypertrophy and fibrosis were also attenuated in rats or experimentally hypertensive rats has also been pre-
receiving kallikrein gene delivery. viously demonstrated [13–15].
Conclusions. These findings indicated that kallikrein gene
Chronic renal failure, whether caused by diabetes,delivery attenuates hypertension and protects against renal
essential hypertension, chronic glomerulonephritis, orinjury and cardiac remodeling in the rat remnant kidney model
of chronic renal failure. other causes, tends to progress steadily to end-stage renal
disease. Systemic and glomerular hypertension and sub-
sequent glomerular hyperfiltration are postulated to playKey words: remnant kidney model, vasodilation, blood pressure, car-
diovascular function, hemodynamics. key mechanistic roles in chronic renal failure in humans
and 5/6 nephrectomized rats [16, 17]. Persistent activa-Received for publication November 9, 1999
tion in the kidney and vasculature of pressor systems,and in revised form February 4, 2000
Accepted for publication March 13, 2000 including the renin-angiotensin-aldosterone system, the
sympathetic nervous system, and endothelin, are path-Ó 2000 by the International Society of Nephrology
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ways by which hypertension arises and/or is maintained dards as stated in the Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Resources,in clinical and experimental chronic renal failure [18–21].
Shimamoto et al found urinary kallikrein excretion de- National Academy of Sciences, Bethesda, MD, USA).
One week after surgery, 5/6 nephrectomized animals werecreased significantly in nephrectomized rats, and a nega-
tive correlation existed between urinary kallikrein level randomly selected for the following three groups: 5/6
reduced renal mass without treatment (RRM group),and blood pressure, indicating that a repressed renal kalli-
krein-kinin system may play a pathophysiological role in rats injected via the tail vein with 1.2 3 1010 plaque-
forming units of adenoviral particles harboring the genechronic renal failure [22]. Studies using an angiotensin-
converting enzyme (ACE) inhibitor in combination with for either human tissue kallikrein (cHK group), or lucif-
erase (Luc group). Morphological and physiological pa-a specific bradykinin B2 receptor antagonist (HOE140,
icatibant) have shown that the renal protective effects rameters were measured in rats sacrificed at weeks 4 and
5 postgene delivery.of ACE inhibition in rat chronic renal failure models
may not be dependent on kinin [23–25]; however, the
Blood pressure measurement and collection ofissue remains controversial, as a recent study strongly
serum and urineimplicated kinin in partially mediating these beneficial
effects [26]. Systolic blood pressure measurements, 24-hour urine
collection, and phlebotomy for serum samples were per-In the present study, we explored remedial effects of
a continuous supply of human tissue kallikrein on cardio- formed as previously described [14, 15].
vascular and renal sequelae in 5/6 nephrectomized rats by
Expression of human tissue kallikrein ininjection of high-efficiency adenovirus harboring human
nephrectomized ratstissue kallikrein cDNA. The results established a sus-
tained blood pressure-lowering effect accompanied by im- Reverse transcription-polymerase chain reaction (RT-
PCR) Southern blot analysis specific for human tissueproved cardiac function and lowered total peripheral vas-
cular resistance. In addition to attenuation of renal injury kallikrein mRNA was performed as previously described
[3]. Levels of human tissue kallikrein in serum or urineand decreased proteinuria, kallikrein delivery to 5/6 ne-
phrectomized rats reduced the development of cardiac were determined by enzyme-linked immunosorbent assay
(ELISA) as previously described [14, 15]. Since the anti-hypertrophy and fibrosis. These findings provide impor-
tant information and a possible therapeutic model for the body to human tissue kallikrein used in the ELISA only
recognizes active kallikrein [14], the immunoreactivetreatment of hypertensive and chronic renal disorders.
kallikrein levels represent active kallikrein.
METHODS Measurements of blood urea nitrogen and urinary
kinin, albumin, NOx, cGMP, and cAMPPreparation of replication-deficient adenoviral vectors
Ad.CMV-cHK and Ad.CMV-Luc Serum levels of urea nitrogen were measured as pre-
viously published [28]. Urinary kinin levels were mea-E1/E3-deleted, replication deficient adenoviruses, in
which the expression of human tissue kallikrein (Ad.CMV- sured by a direct kinin radioimmunoassay [14]. Radioim-
munossays of urinary albumin, cAMP, and cGMP levelscHK) or luciferase (Ad.CMV-Luc) cDNA was under
control of the cytomegalovirus enhancer/promoter, were were conducted according to previously described proce-
dures [29, 30]. Urinary NOx content was measured byconstructed as previously described [14].
a fluorometric assay for nitrite/nitrate [31].
Reduced renal mass model and experimental protocol
Fluorescent microsphere determinationsMale Wistar rats weighing between 175 and 225 g
of hemodynamics(Sprague-Dawley Harlan, Indianapolis, IN, USA) were
used in this study; 5/6 renal mass reduction was per- Hemodynamic parameters were assessed in rats one
week following gene delivery. Fluorescent microspheresformed (N 5 67) as previously published [27], beginning
with infarction of approximately two thirds of the left with a diameter of 15 mm (Molecular Probes Inc., Eugene,
OR, USA) were injected essentially as previously de-kidney by ligation of the posterior and one or two ante-
rior extrarenal branches of the main renal artery. One scribed [32]. A microsphere solution (0.2 mL, approxi-
mately 2 3 105 microspheres/mL in 0.9% saline 1 0.02%week later, a right unilateral nephrectomy was per-
formed. A control group (sham) of 17 rats underwent Tween 20) was injected into the left ventricle at a rate
of 0.29 mL/mine. A saline flush followed at the samesham operations consisting of laparotomy and manipula-
tion of the renal pedicles. Anesthesia for surgical proce- rate for 140 seconds. A reference blood sample was with-
drawn via the left femoral artery at a rate of 0.29 mL/mindures was accomplished by intraperitoneal injection of
ketamine (9 mg/100 g body weight)/xylazine (1 mg/100 g for 180 seconds starting at the same time as microsphere
injection. Samples were processed by the sedimentationbody weight). All procedures complied with the stan-
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method as directed by the manufacturer (Molecular rats receiving adenovirus containing the luciferase gene
(N 5 4, P , 0.05).Probes). Cardiac output (CO) was calculated as follows:
CO 5 Qr 3 FluorI 3 Fluorr21 Expression of human tissue kallikrein after
gene deliverywhere Qr is the reference blood flow, FluorI is total in-
jected fluorescence, and Fluorr reference fluorescence. Expression of human tissue kallikrein mRNA in 5/6
nephrectomized rats one week following gene deliveryCO was correlated to body weight and expressed as
cardiac index (CI) 5 CO 3 weight21. Total peripheral was detected by RT-PCR followed by Southern blot
analysis using oligonucleotides specific for human tissueresistance index (TPRI) was calculated as mean arterial
pressure (MAP) 3 CI21. Regional blood flow (mL/min/ kallikrein. Figure 2 shows that human kallikrein can be
detected in the heart, aorta, lung, kidney, and liver (up-100 g) to tissues was calculated as 5 (FluorTiss/WtTiss)
(Qr/Fluorr)100. per panel, left). The RT-PCR products from rats receiv-
ing the luciferase gene did not hybridize to the human
Morphological analysis tissue kallikrein gene probe (upper panel, right). These
results indicate that Southern blot analysis is specificLeft ventricle weight to whole heart weight ratio was
determined as previously described [15]. Sections of left for human tissue kallikrein, and endogenous rat tissue
kallikrein family members do not interfere with the assay.ventricle were silver stained, and cardiomyocyte diameters
were measured as previously published [15]. Glomerular Similar levels of b-actin mRNA were detected in tissues
of both experimental and control groups, indicating anlesions were graded in periodic acid-Schiff (PAS)-stained
sections of kidney in a single-blind manner using a scale acceptable quality and similar quantity of RNA in these
samples (lower panel). Following intravenous injectionof 0 (normal) to 5 (severely sclerotic), essentially as for-
merly described [33]. Thirty randomly selected glomeruli of Ad.CMV-cHK into nephrectomized rats, recombinant
human tissue kallikrein levels in rat sera and urine werewere graded for each rat, and the final glomerular sclero-
sis score for each group was calculated from weighted measured by a specific ELISA. Human tissue kallikrein
was detected from 3 to 14 days postgene delivery withvalues based on the percentage of glomeruli falling into
each severity grade (0 through 5). Left ventricular fibro- a peak level of 463 6 76 ng/mL on day 3 (N 5 4 to 6).
Human tissue kallikrein was detected in rat urine at 4-,sis was assessed in low-power (31.25 objective) fields
of Masson’s trichrome-stained cross-sections in Adobe 11-, and 17-days post-gene delivery (703 6 260, 53.6 6
27.4, 12.7 6 12.7 ng/mL, respectively, N 5 7). LinearPhotoShop to determine the percentage of collagen (blue)
staining area to total tissue area. displacement curves of a serial dilution of rat sera and
urine from rats injected with the kallikrein gene were
Statistical analysis parallel to the purified human tissue kallikrein standard,
indicating their immunologic identity (data not shown).Results are expressed as mean 6 SEM. Comparisons
among groups were made by analysis of variance with Human tissue kallikrein was not detected in sera or urine
of control rats receiving the luciferase gene. These resultsFisher’s protected least significant difference (PLSD).
Differences were considered significant at P , 0.05. indicated that the antihuman tissue kallikrein antiserum
did not cross-react with the members of the rat kallikrein
gene family.
RESULTS
Blood pressure reduction after intravenous injection Ad.CMV-cHK gene delivery increases urinary kinin,
NOx, and cGMPof Ad.CMV-cHK adenovirus
Figure 1 shows systolic blood pressures of nephrecto- Figure 3 demonstrates that urinary excretion of kinin,
nitrate/nitrite (NOx), and cGMP were significantly in-mized rats before and after adenovirus-mediated kalli-
krein gene delivery. Prior to gene delivery, the systolic creased in nephrectomized rats receiving Ad.CMV-cHK
as compared with nephrectomy alone or rats receivingblood pressure of nephrectomized rats was significantly
higher (181 6 3 mm Hg, N 5 44, P , 0.001) than that Ad.CMV-Luc injection. Assays were done one week fol-
lowing gene delivery. The data indicate that kallikreinof sham-operated rats (145 6 4 mm Hg, N 5 11). One
week after adenovirus administration, a maximal blood gene delivery resulted in increased production of kinin
with subsequent effects, such as lowered blood pressure,pressure reduction of 37 mm Hg (159 6 5 vs. 196 6 6
mm Hg, P , 0.001) was observed in rats receiving the being mediated by a NO-cGMP signaling pathway. Lev-
els of urinary cAMP did not differ significantly amongkallikrein gene (cHK, N 5 14), as compared with rats
receiving the luciferase gene (Luc, N 5 15). Five weeks experimental groups (RRM 5 230 6 24, Luc 5 337 6
92, cHK 5 357 6 153 ng/day/100 g body wt). The levelpostdelivery remnant kidney rats receiving cHK (N 5 6)
maintained a 17 mm Hg (204 6 6 vs. 226 6 7 mm Hg, of NOx is intended as an indirect measurement of NO
production.P , 0.05) reduction in blood pressure compared with
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Fig. 1. Systolic blood pressure of sham-oper-
ated, 5/6 nephrectomized (reduced renal mass;
RRM) rats or nephrectomized rats receiving
adenoviral vectors harboring the gene for hu-
man tissue kallikrein (cHK) or luciferase (Luc)
via tail vein injections. Systolic blood pressure
values are expressed as mean 6 SEM (N 5
6 to 14). Symbols are: (h) cHK; (j) Luc; (s)
RRM; (d) sham. *P , 0.01 vs. RRM and Luc;
**P , 0.05 vs. RRM and Luc.
be consistent with the ability of kinin generation to cause
an overall vasodilation in the peripheral vasculature,
thereby lowering systemic blood pressure, decreasing
vascular resistance and cardiac preload and afterload,
and increasing regional blood flow.
Decreased BUN in rats receiving kallikrein
gene delivery
Figure 5 shows levels of urea nitrogen in serum of rats
over the time course of the study. One week following
surgery, BUN levels showed no significant differenceFig. 2. Expression of human tissue kallikrein mRNA in nephrectomized
between rats with surgery alone and those assigned torats after gene delivery. Total RNA was isolated from heart, aorta,
lung, kidney, and liver, and 1 mg was used for RT-PCR, followed by receive adenovirus, denoting a uniform effect of surgery.
Southern blot analysis.
Following gene delivery, rats receiving Ad.CMV-cHK
showed significantly decreased BUN levels, indicating
enhanced renal function as compared with the control
Improvement in hemodynamic parameters following nephrectomized rats (RRM and Luc).
kallikrein gene delivery
Kallikrein gene delivery attenuates renal injuryThe changes in cardiac index (A), total peripheral
Table 1 shows that five-weeks after gene delivery, thevascular resistance (B), regional blood flow to the kidney
group receiving kallikrein gene delivery had significantly(C) and gastrocnemius muscle (D) are shown in Figure 4.
less proteinuria than rats with nephrectomy alone (P ,Kallikrein gene delivery improved cardiac function as
0.05) or those receiving luciferase gene delivery (P , 0.05).evidenced by a significant increase in cardiac index (P ,
Urinary levels of albumin corroborate these results, as0.05 for cHK compared with Luc, N 5 5 and 4, respec-
a similar reduction of albuminuria in the cHK group astively) and reduced total peripheral vascular resistance
compared with RRM (P , 0.05) and Luc (P , 0.01)(P , 0.05 compared to Luc). A significant increase in
was seen. Quantitation of glomerular sclerosis in ne-regional blood flow to the kidney and gastrocnemius
phrectomized rats five weeks after gene delivery revealedmuscle was also found after Ad.CMV-cHK administra-
tion (P , 0.05 compared with Luc). These results would a significant decrease in glomerular sclerotic injury in
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Fig. 3. Urinary excretion of kinin (A), nitric oxide (NOx; B), and cGMP (C) one week following gene delivery. Groups include sham operated
(Sham), nephrectomy alone (RRM), and nephrectomized animals receiving gene delivery of human tissue kallikrein (cHK) or luciferase (Luc).
Data are expressed as mean 6 SEM (N 5 6 to 8 per group).
rats receiving kallikrein as compared with RRM (P , not shown) as compared with shams, and the kallikrein
group was intermediate.0.05) and Luc (P , 0.05).
Figure 6 shows kidney sections stained with PAS (re-
Kallikrein attenuates cardiac hypertrophy and fibrosisnal cortex; row A) or Masson’s trichrome (renal medulla;
row B) to illustrate the beneficial effects of kallikrein Figure 7 shows a typical histologic appearance of Mas-
son’s trichrome-stained cross-sections of the left ventri-delivery on renal morphology in nephrectomized rats.
PAS staining of carbohydrates enables examination of cle. Masson’s trichrome stains cells red and extracellular
matrix, such as collagen, blue. The sham-operated heartstubular brush borders, basement membranes, and glomer-
ular sclerosis. Normal morphology was seen in the cortex appeared morphologically normal. Blue areas of focal
fibrosis, like that shown in the middle micrograph inof sham-operated rats (left panel). The renal cortex of
nephrectomized rats receiving luciferase gene delivery Figure 7, were routinely seen in nephrectomized rats of
the RRM (data not shown) and Ad.CMV-Luc groups.showed a number of injuries, including proximal tubular
damage and loss of brush border, tubular dilation, glo- Increased blue in interstitial areas was also noted. Blue
staining and the size and number of focal areas of fibrosismerular sclerosis, the formation of protein casts in tubules,
and interstitial inflammation (middle panel). These injur- were reduced in rats receiving kallikrein gene delivery.
Quantitation of blue stain as a percentage of the totalies were also typical in sections of kidney from the RRM
group (data not shown), which morphologically did not tissue area was used as an indicator of left ventricular
fibrosis. A significant decrease in blue staining of extra-differ from the luciferase group. Kallikrein gene delivery
in nephrectomized rats reduced tubular dilation, brush cellular matrix, as indicated in Table 1, was evident in
the cHK (N 5 6) group as compared with RRM (P ,border disruption, glomerular sclerosis, and interstitial
inflammation. Protein casts were reduced both in num- 0.001, N 5 6) and Luc (P , 0.001, N 5 4) groups. Two
complete cross-sections of ventricle were evaluated perber and size in the kallikrein group.
In trichrome-stained sections of the medulla (Fig. 6, animal for a minimum of eight sections per group.
Table 1 also shows the significantly increased left ven-row B) of nephrectomized rats in the luciferase group,
a severe progressive interstitial inflammation and tubular tricular weight in rats with nephrectomy alone or nephrec-
tomy and luciferase gene delivery as compared with sham-degeneration were evident. Morphologically RRM rats
(data not shown) did not differ from the rats receiving operated rats or nephrectomized rats receiving kallikrein
gene delivery (P , 0.05, N 5 4 to 6 per group). Kallikreinluciferase. An increased level of extracellular matrix such
as collagen, which stains blue, was evident as compared gene delivery also reduced the increase in cardiomyocyte
diameter resulting from nephrectomy (P , 0.01 for RRMwith the tissue kallikrein group, indicating a greater level
of fibrosis. The number of tubules was quite noticeably and for RRM 1 Luc as compared with sham or cHK).
Forty cardiomyocytes per animal were measured for afewer per field in the luciferase and RRM groups (data
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Fig. 4. Hemodynamic parameters measured by fluorescent microspheres one week after gene delivery. Animals include sham-operated controls
(sham) or animals that underwent 5/6 nephrectomy received and one week later adenovirus mediated gene delivery for tissue kallikrein (cHK)
or the luciferase control virus (Luc). Data are expressed as mean 6 SEM (N 5 4 to 5).
total of at least 160 per group. The decrease in left ven- remodeling in 5/6 nephrectomized rats. The blood pres-
sure-lowering effect was achieved within one week andtricular weight and average cardiomyocyte diameter in-
continued for five weeks following kallikrein gene deliv-dicate that kallikrein gene delivery attenuates the devel-
ery. Tissue kallikrein mRNA was located in the liver asopment of cardiac hypertrophy.
well as in tissues involved in cardiovascular and renal
function, such as the heart, kidney, and aorta. High levels
DISCUSSION of immunoreactive human tissue kallikrein were de-
This study shows that a single intravenous injection tected in the serum and urine of rats receiving kallikrein
of recombinant adenovirus harboring the human tissue gene transfer, indicating secretion of human kallikrein
kallikrein gene resulted in a sustained reduction of blood from the liver and kidney. Morphological analysis of
kidney sections demonstrated that somatic gene deliverypressure and protection against renal injury and cardiac
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Fig. 5. Time course of BUN levels. Groups
include sham operated (d), nephrectomy
alone (RRM; s), and nephrectomized ani-
mals receiving gene delivery of human tissue
kallikrein (cHK; h) or luciferase (Luc; j).
Data are expressed as mean 6 SEM (N 5 4
or 5 per group). **P , 0.005 vs. RRM and
Luc; *P , 0.001 vs RRM and Luc.
Table 1. Indices of renal and cardiac injury
Parameters Sham RRM Ad.CMV-Luc Ad.CMV-cHK
Urinary protein mg/day/100 g body weight 1261 76620 69615 2563a
Urinary albumin mg/day/100 g body weight 0.660.1 32.768.4 27.165.9 9.862.3a
Glomerular sclerotic score 1.361.3 44.862.8 41.863.7 28.664.2a
Left ventricle weight/heart weight 0.6760.01 0.7260.01 0.7260.02 0.6660.01a
Myocyte diameter lm 17.160.24 20.960.51 21.060.58 19.060.68a
Left ventricle fibrosis % 0.4860.02 2.6760.23 2.7260.26 0.9960.10b
Measurements are shown as mean 6 SEM. All measurements above were made five weeks after gene delivery (N 5 4 to 6 per group).
a P , 0.05
b P , 0.001 as compared with RRM and Ad.CMV-Luc groups
Glomerular lesions were graded using a scale of 0 (normal) to 5 (severely sclerosed), and the final glomerular sclerosis score for each group was calculated from
weighted values based on the percentage of glomeruli falling into each severity grade (0 through 5). For left ventricle fibrosis, extracellular matrix was measured in
Masson’s trichrome-stained sections as the total blue stained area/total tissue area. Groups include sham operated (sham), nephrectomy alone (RRM), and nephrecto-
mized animals receiving gene delivery of human tissue kallikrein (cHK) or luciferase (Luc). Data are expressed as mean 6 SEM.
of human tissue kallikrein attenuated glomerular scle- protective effects against cardiovascular remodeling and
renal damage in the reduced renal mass model.rosis, tubulointerstitial inflammation, tubular dilation,
brush border disruption, tubular protein cast formation, Although the therapeutic value of reducing systemic
blood pressure in the management of chronic renal dis-and reduced proteinuria. Left ventricular hypertrophy
and fibrosis were also reduced in rats receiving kallikrein. ease is well established, locally enhancing the actions
of the renal kallikrein-kinin system may also play anThese findings showed that kallikrein gene delivery has
c
Fig. 6. Representative histologic sections of kidney cortex and medulla. Five weeks after gene delivery, PAS-stained sections of renal cortex (A)
and Masson’s trichrome-stained sections of renal medulla (B) were evaluated for renal damage such as thickened basement membranes and
glomerular sclerosis, dilated tubules and disrupted brush borders, protein casts (indicated by small arrows) and interstitial inflammation (indicated
by larger arrow heads; 3225).
c
Fig. 7. Representative histologic cross sections of left ventricle stained by Masson’s trichrome method. Heart morphology five weeks after gene
delivery is presented for sham groups and nephrectomized animals receiving adenovirus harboring human tissue kallikrein (cHK) or luciferase
(Luc). Cytoplasm stains red, while extracellular matrix (collagen) stains blue (3200).
Wolf et al: Kallikrein gene delivery in chronic renal failure 737
Wolf et al: Kallikrein gene delivery in chronic renal failure738
important role in the ability of kallikrein gene therapy readministration. Recently, modified adenoviral vectors
have been shown to produce prolonged transgene ex-to slow the progression of renal failure. Kinin has been
previously shown to vasodilate glomerular vessels [34, 35], pression with markedly reduced immune and inflamma-
tory responses [41]. Therefore, the development of im-and it has been postulated that by lowering glomerular
pressure kinin generation can locally mediate renal pro- proved adenoviral vectors harboring the human tissue
kallikrein gene potentially could be used for studying thetection [33, 36]. Angiotension-converting enzyme (ACE)
inhibitors are especially effective in the management of role of kallikrein in cardiovascular and renal functions as
well as establishing long-term therapeutic potential.chronic renal failure patients. A number of studies using
ACE inhibitors in combination with the highly specific
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